GlaxoSmithKline hits speed bump en route to diabetes drug approval

GlaxoSmithKline ($GSK) hit a roadblock in its bid for approval on a new diabetes drug. The FDA asked for a few more months to review GSK's app on albiglutide, which would compete with Novo Nordisk's ($NVO) Victoza and Bristol-Myers Squibb ($BMY) and AstraZeneca's ($AZN) Byetta and Bydureon, among others. Report